Top of the morning to you, and a fine one it is. After a quick out-of-town speaking engagement, we have happily returned to the Pharmalot campus, where we awoke to sunny skies and a bit of a nip in the air. Certainly nice to be back in the groove, as they say, and to celebrate, we have fired up the coffee kettle to enjoy a cup or three of stimulation. Feel free to join us. After all, no prescription is required. So no need to fuss over rebates or authorization to try a different flavor. Meanwhile, here are some tidbits. Hope all goes well and do keep in touch.

As voting neared on the House drug pricing bill, the legislation has prompted a barrage of advertising from the pharmaceutical industry in newspapers that circulate in Washington, D.C., STAT reports. The ads are unlikely to prevent the House from passing the bill, but are emblematic of a larger truth in Washington: Never underestimate deep industry pockets when it comes to drug pricing legislation. And the last-minute blitz is already being decried by drug pricing advocates.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy